Artelo Biosciences Inc Stock News

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living w...

Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having st...

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be...

ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies

SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helpin...

SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that it will be participating in the Maxim Group 2024 Virtual Healthcare Summit being held Octobe...

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright ...

SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a busin...